IP Verse

Combination Drug - EP3246047

The patent EP3246047 was granted to Chugai Seiyaku Kabushiki Kaisha on Dec 25, 2024. The application was originally filed on Jan 15, 2016 under application number EP16737446A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3246047

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP16737446A
Filing Date
Jan 15, 2016
Status
Granted And Under Opposition
Nov 22, 2024
Publication Date
Dec 25, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOTTI & FERRARISep 24, 2025BOTTI & FERRARIADMISSIBLE

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTJP2012072140
OPPOSITIONWO2012042421

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- SUBBIAH VIVEK ET AL, "STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.", JOURNAL OF HEMATOLOGY & ONCOLOGY 11 JUN 2015, (20150611), vol. 8, ISSN 1756-8722, page 66
EXAMINATION- SUBBIAH VIVEK ET AL, "Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (2016), Database accession no. NLM27764830, XP002782755
EXAMINATION- SUBBIAH VIVEK ET AL, "Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.", ONCOLOGY 2016, (2016), vol. 91, no. 6, doi:10.1159/000449204, ISSN 1423-0232, pages 348 - 353, XP002782755
EXAMINATION- SUBBIAH VIVEK ET AL, "STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (20150611), Database accession no. NLM26062823, XP002782754
INTERNATIONAL-SEARCH-REPORT- CIAMPORCERO E et al., "Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models", Molecular Cancer Therapeutics, (20141107), vol. 14, no. 1, ISSN 1538-8514, pages 101 - 110, XP 055466172 [X] 1-11, 20, 22-31, 33-36, 38, 39, 50, 51 [Y] 14-20, 42-49
INTERNATIONAL-SEARCH-REPORT- HIROOMI KANAYAMA, "VEGF/VEGFR Hyoteki Chiryoyaku-Jinsaibo Gan deno Chiryo Seiseki to Kongo no Chiryo Senryaku", Experimental Medicine, (20110000), vol. 29, no. 2, ISSN 0288-5514, pages 359 - 366, XP 009504747 [Y] 14-20, 42-49
INTERNATIONAL-SEARCH-REPORT- HIROSHI SAKAMOTO, "Keyword Kaisetsu ''ALK inhibitor", Folia Pharmacologica Japonica, (20130000), vol. 142, no. 1, ISSN 0015-5691, pages 48 - 50 [Y] 1-51
INTERNATIONAL-SEARCH-REPORT- MARTINENGO C et al., "ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis", Cancer Research, (20140905), vol. 74, no. 21, ISSN 1538-7445, pages 6094 - 6106, XP 055466185 [Y] 1-51
INTERNATIONAL-SEARCH-REPORT- NAKADE J et al., "Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF- triggered, erlotinib-resistant lung cancer harboring an EGFR mutation", Journal of Thoracic Oncology, (20140600), vol. 9, no. 6, ISSN 1556-1380, pages 775 - 783, XP 002747688 [X] 1-11, 14-20, 22-31, 33-36, 38, 39, 42-51
INTERNATIONAL-SEARCH-REPORT- NORIKO YANAGITANI et al., "ALK Sogaiyaku", Pharma Medica, (20140000), vol. 32, no. 11, ISSN 0289-5803, pages 33 - 35, XP009504737 [Y] 1-51
OPPOSITION- Anonymous, "Xalkori - crizotinib - Summary of opinion1 (initial authorisation) ", EMA/CHMP/453868/2012, Committee for Medicinal Products for Human Use (CHMP), (20120719), EMA/CHMP/453868/2012, Committee for Medicinal Products for Human Use (CHMP) , URL: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xalkori_en.pdf, XP093321010
OPPOSITION- Minoo Parham, Wang Huan-You, "ALK-immunoreactive neoplasms", International Journal of Clinical and Experimental Pathology, E-Century Publishing Corporation, US, US , (20120615), vol. 5, no. 5, ISSN 1936-2625, pages 397 - 410, XP093321000
OPPOSITION- Nicholas H. G. Holford, "Chapter 3: Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Actio", Basic & Clinical Pharmacology, US, McGraw-Hill Medical, (20120101), pages 37 - 51, ISBN 978-0-07-176402-5, XP009555925
OPPOSITION- von Zastrow, Mark, "Chapter 2: Drug Receptors / Pharmacodynamics", Basic & Clinical Pharmacology, US, McGraw-Hill Medical, (20120101), pages 15 - 35, ISBN 978-0-07-176401-8, XP009555924
OPPOSITION- Marianne I. Martić-Kehl; Roger Schibli; P. August Schubiger, "Can animal data predict human outcome? Problems and pitfalls of translational animal research", European Journal of Nuclear Medicine and Molecular Imaging, Springer, Berlin, DE, Berlin, DE , (20120713), vol. 39, no. 9, doi:10.1007/s00259-012-2175-z, ISSN 1619-7089, pages 1492 - 1496, XP035094686
OPPOSITION- Mckeage Kate, "Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer", Drugs, Adis International, Auckland, Auckland, (20150101), vol. 75, no. 1, doi:10.1007/s40265-014-0329-y, ISSN 0012-6667, pages 75 - 82, XP093320996
OPPOSITION- Moskovits Neta; Peretz Idit; Chausky Eva; Itzhaki Ella; Shmuel Nofar; Meerson Raisa; Tarasenko Nataly; Kaufman Aleksandr; Stemmer Amos; Yaffe Ranny; Bareket-Samish Avital; Edison Natalia; Goldman Tal; Stemmer Salomon M., "Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types", Cancer letters, NEW YORK, NY, US, US , (20220328), vol. 536, doi:10.1016/j.canlet.2022.215665, ISSN 0304-3835, XP087020877
OPPOSITION- Diana Duarte et al., "Evaluation of synergism in drug combinations and reference models for future orientations in oncology", Current Research in Pharmacology and Drug Discovery, (2022), vol. 3, doi:10.1016/j.crphar.2022.100110, XP093055997
OPPOSITION- C. Martinengo, Poggio T., Menotti M., Scalzo M. S., Mastini C., Ambrogio C., Pellegrino E., Riera L., Piva R., Ribatti D., Pastorino F., Perri P., Ponzoni M., Wang Q., Voena C., Chiarle R., "ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis", Cancer Research, American Association for Cancer Research, (20141101), vol. 74, no. 21, doi:10.1158/0008-5472.CAN-14-0268, ISSN 0008-5472, pages 6094 - 6106, XP055466184
OPPOSITION- M. Mori, Y. Ueno, S. Konagai, H. Fushiki, I. Shimada, Y. Kondoh, R. Saito, K. Mori, N. Shindou, T. Soga, H. Sakagami, T. Furutani, H. Doihara, M. Kudoh, S. Kuromitsu, "The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20140201), vol. 13, no. 2, doi:10.1158/1535-7163.MCT-13-0395, ISSN 1535-7163, pages 329 - 340, XP055469118
SEARCH- SUBBIAH VIVEK ET AL, "Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.", ONCOLOGY, (2016), vol. 91, no. 6, doi:10.1159/000449204, ISSN 1423-0232, pages 348 - 353, XP002782755 [XP] 1,3,6-8,11,12,17-19,21,30 * the whole document * [I] 2,4,5,9,10,13-16,20,22-29
SEARCH- SUBBIAH VIVEK ET AL, "STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.", JOURNAL OF HEMATOLOGY & ONCOLOGY, (20150611), vol. 8, doi:10.1186/s13045-015-0160-2, ISSN 1756-8722, pages 1 - 7, XP002782754 [XP] 1,3,6-8,11,12,17-19,30 * the whole document * [I] 2,4,5,9,10,13-16,20-29

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents